TY - JOUR

T1 - A systematic review of health-related quality of life in longitudinal studies of myeloma patients

AU - Nielsen, Lene Kongsgaard

AU - Jarden, Mary

AU - Andersen, Christen Lykkegaard

AU - Frederiksen, Henrik

AU - Abildgaard, Niels

PY - 2017

Y1 - 2017

N2 - ObjectivesMultiple myeloma (MM) patients report high symptom burden and reduced health-related quality of life (HRQoL) compared to patients with other haematological malignancies. The aim of this review was to analyse published longitudinal studies including MM patients according to a change in HRQoL scores, which is perceived as beneficial to the patient according to two published guidelines.MethodsA literature search was performed May 2016. Publications with longitudinal follow-up using the EORTC QLQ-C30 instrument for HRQoL measurement of physical functioning, global quality of life, fatigue and/or pain were included. An analysis of mean change from baseline was carried out according to minimal important difference (MID).ResultsLarge and medium HRQoL improvements were reported during first-line treatments. No clinically beneficial change or deteriorations in scores of global QoL or fatigue were reported during relapse treatment. HRQoL data during maintenance therapy are sparse and inconclusive.ConclusionsGuidelines for interpreting changes in HRQoL including definitions of MID have been developed; however, consensus is missing. Improvements in HRQoL are far more likely to occur during first-line compared to relapsed treatment regimens. The background of these findings should be in focus in future studies, and HRQoL measurements should be integrated in maintenance studies.

AB - ObjectivesMultiple myeloma (MM) patients report high symptom burden and reduced health-related quality of life (HRQoL) compared to patients with other haematological malignancies. The aim of this review was to analyse published longitudinal studies including MM patients according to a change in HRQoL scores, which is perceived as beneficial to the patient according to two published guidelines.MethodsA literature search was performed May 2016. Publications with longitudinal follow-up using the EORTC QLQ-C30 instrument for HRQoL measurement of physical functioning, global quality of life, fatigue and/or pain were included. An analysis of mean change from baseline was carried out according to minimal important difference (MID).ResultsLarge and medium HRQoL improvements were reported during first-line treatments. No clinically beneficial change or deteriorations in scores of global QoL or fatigue were reported during relapse treatment. HRQoL data during maintenance therapy are sparse and inconclusive.ConclusionsGuidelines for interpreting changes in HRQoL including definitions of MID have been developed; however, consensus is missing. Improvements in HRQoL are far more likely to occur during first-line compared to relapsed treatment regimens. The background of these findings should be in focus in future studies, and HRQoL measurements should be integrated in maintenance studies.

KW - Health-related quality of life

KW - multiple myeloma

KW - longitudinal studies

KW - DIAGNOSED MULTIPLE-MYELOMA

KW - STEM-CELL TRANSPLANTATION

KW - LOW-DOSE DEXAMETHASONE

KW - RESPONSE SHIFT

KW - CLINICAL-TRIALS

KW - EUROPEAN-ORGANIZATION

KW - PHASE-II

KW - LENALIDOMIDE

KW - BORTEZOMIB

KW - MELPHALAN

U2 - 10.1111/ejh.12882

DO - 10.1111/ejh.12882

M3 - Review

VL - 99

SP - 3

EP - 17

JO - Scandinavian Journal of Haematology

JF - Scandinavian Journal of Haematology

SN - 0902-4441

IS - 1

ER -